Ellen N Liggett,N Leigh Anderson,Alistair Bailey,Perdita Barran,Philip Brownbridge,Kathleen Cain,Rachel S Carling,Rainer Cramer,R Neil Dalton,Matthew E Daly,Kayleigh Davis,Ivan Doykov,Maria Emilia Dueñas,Edward Emmott,Claire E Eyers,Akshada Gajbhiye,Bethany Geary,Pankaj Gupta,Jenny Hällqvist,Evita Hartmane,Simon Heales,Tiaan Heunis,Wendy Heywood,Katherine A Hollywood,Rosalind E Jenkins,Donald JL Jones,Brian Keevil,Henriette Krenkel,Dan Lane,Catherine S Lane,Sophie Lellman,Xiaoli Meng,Clare Mills,Kevin Mills,Atakan A Nalbant,Leong L Ng,Benjamin Nicholas,Dan Noels,Terry W Pearson,Andrew Pitt,Matthew E Pope,Andrew Porter,George W Preston,Morteza Razavi,Andrew Shapanis,Frances R Sidgwick,Raj Singh,Paul Skipp,Reynard Speiss,Justyna Spiewak,Anna L Tierney,Drupad Trivedi,Matthias Trost,Richard D Unwin,Luke Wainwright,Caitlin Walton-Doyle,Anthony D Whetton,Sandra Wilks,Richard Yip

Abstract:During the COVID-19 pandemic, development of diagnostic tests was vital to chart the course and to reduce the impact of the infection. Continued testing and surveillance of vaccine escape will continue for years to come which presents an opportunity to integrate such testing into clinical biochemistry laboratories that form part of integrated healthcare testing. Here we describe a protocol for a targeted mass spectrometry based proteomic assay (COVIDCAP) developed to detect SARS-CoV-2 peptides from oro-nasopharyngeal swabs (ONP) and saliva. This uses novel SISCAPA antibodies bound to magnetic beads and subsequent analysis of captured and purified SARS-CoV-2 nucleocapsid (NCAP) peptides. The method involves immediate deactivation of the sample using an ethanolic solution. This simultaneously inactivates the virus and denatures viral proteins at sampling in contrast to the approach for RT-PCR testing, with benefits for the assay as well as for downstream processing. A plate-based preparation of the samples involving acetone precipitation followed by a short tryptic digestion and subsequent immunocapture allows LC-MS detection and quantification of peptides from the NCAP protein, in a 3-minute inject-to-inject assay with an LOD of 20 attomoles from starting sample. For 576 ONP swab samples taken as exemplars here, the sensitivity and specificity of this analysis is shown to be 97.0% and 96.6% respectively.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a method based on liquid chromatography - mass spectrometry (LC - MS/MS) in a clinical setting for the detection of SARS - CoV - 2 antigens from oropharyngeal - nasopharyngeal (ONP) swabs and saliva. Specifically, the objectives of the paper include: 1. **Improve diagnostic efficiency**: By developing a rapid, highly sensitive and specific method that can effectively detect SARS - CoV - 2 antigens to assist in patient prognosis and public health measures. 2. **Simplify sample processing**: Use an ethanol solution to inactivate the virus immediately at the sampling site while denaturing the viral proteins, simplifying the subsequent processing steps. 3. **Adapt to clinical laboratories**: Ensure that the method can be implemented in a routine clinical biochemistry laboratory without the need for additional complex training and is capable of high - throughput (HT) screening. 4. **Compare with existing methods**: Evaluate the sensitivity and specificity of this method compared to the current gold - standard real - time reverse - transcription polymerase chain reaction (RT - PCR) method. ### Specific objectives - **Sample collection and processing**: Develop a method that can inactivate the virus immediately at the sampling site, using a 70:30 ethanol - ammonium acetate solution to collect ONP swab and saliva samples. - **Protein extraction and digestion**: Use acetonitrile to precipitate proteins and then perform a short - time digestion with trypsin. - **Immune capture**: Use SISCAPA (Stable Isotope Standards and Capture by Anti - Peptide Antibodies) technology to capture selected SARS - CoV - 2 nucleocapsid (NCAP) peptides via magnetic beads. - **Mass spectrometry analysis**: Use liquid chromatography - tandem mass spectrometry (LC - MS/MS) to detect and quantify NCAP peptides, with a method having an injection - to - injection time of 3 minutes and a detection limit of 20 attomoles. - **Performance verification**: Analyze 576 ONP swab samples, and the results show that the sensitivity and specificity of this method are 97.0% and 96.6% respectively. ### Background During the COVID - 19 pandemic, rapid and accurate diagnostic tests are crucial for controlling the epidemic. Although RT - PCR is considered the gold standard, it has the risks of false - negative and false - positive results, and may face problems of insufficient reagent supply in large - scale population testing. Therefore, developing alternative detection methods, such as mass - spectrometry - based techniques, can improve the diversity and resilience of diagnosis. ### Method advantages - **High sensitivity and specificity**: Mass spectrometers have high sensitivity and high specificity, which are suitable for multi - target analysis. - **Versatility**: Mass spectrometry techniques have been widely used in clinical laboratories for applications such as neonatal screening and immunosuppressive drug monitoring. - **Rapid and efficient**: This method can complete an injection - to - injection analysis within 3 minutes, which is suitable for high - throughput screening. In conclusion, this paper aims to develop a rapid, accurate and easy - to - implement LC - MS/MS method for detecting SARS - CoV - 2 antigens to supplement the existing RT - PCR detection methods and improve the diversity and reliability of diagnosis.

Development and translation of a method of clinical utility for LC-MS/MS analysis to detect SARS-CoV-2 antigens from ONP swabs and saliva

Operation Moonshot: rapid translation of a SARS-CoV-2 targeted peptide immunoaffinity liquid chromatography-tandem mass spectrometry test from research into routine clinical use

Proteotyping SARS-CoV-2 virus from nasopharyngeal swabs: a proof-of-concept focused on a 3 min mass spectrometry window

A high throughput immuno-affinity mass spectrometry method for detection and quantitation of SARS-CoV-2 nucleoprotein in human saliva and its comparison with RT-PCR, RT-LAMP, and lateral flow rapid antigen test

A targeted LC-MRM 3 proteomic approach for the diagnosis of SARS-CoV-2 infection in nasopharyngeal swabs

Lateral flow–based nucleic acid detection of SARS-CoV-2 using enzymatic incorporation of biotin-labeled dUTP for POCT use

Development of a High-Throughput Mass Spectrometry-Based SARS-CoV-2 Immunoassay

Rapid Development and Validation of a Novel Laboratory-Derived Test for the Detection of SARS-CoV-2

Development of an Integrated Sample Amplification Control for Salivary Point-of-Care Pathogen Testing

RT-PCR/MALDI-TOF mass spectrometry-based detection of SARS-CoV-2 in saliva specimens

MALDI-TOF Mass Spectrometric Detection of SARS-CoV-2 Using Cellulose Sulfate Ester Enrichment and Hot Acid Treatment

Development and Clinical Validation of RT-LAMP-Based Lateral-Flow Devices and Electrochemical Sensor for Detecting Multigene Targets in SARS-CoV-2

Identification of Endogenous Peptides in Nasal Swab Transport Media used in MALDI-TOF-MS Based COVID-19 Screening.

Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for the Detection of SARS-CoV-2

Isothermal Amplification and Ambient Visualization in a Single Tube for the Detection of SARS-CoV-2 Using Loop-Mediated Amplification and CRISPR Technology

Development and validation of a highly sensitive and specific electrochemical assay to quantify anti-SARS-CoV-2 IgG antibodies to facilitate pandemic surveillance and monitoring of vaccine response.

Pre-clinical and clinical evaluation of a surface plasmon field-enhanced fluorescence spectroscopy (SPFS) antigen test for detecting SARS-CoV-2

Rapid, Portable, and Electricity-free Sample Extraction Method for Enhanced Molecular Diagnostics in Resource-Limited Settings

Clinical Utility of a Highly Sensitive Lateral Flow Immunoassay as determined by Titer Analysis for the Detection of anti-SARS-CoV-2 Antibodies at the Point-of-Care

Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients with COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism.